IL17A and inflammatory bowel disease: A total number of 388 cases of gastrointestinal inflammatory events in the context of IL-17 inhibitor therapy were reported, of which 268 were IBD due to biologic therapy with secukinumab (ROR = 2.13, 95% CI [1.96–2.30]) and ixekizumab (ROR = 2.79, 95% CI [2.39–3.27]) [57].